Strides Pharma Science バランスシートの健全性
財務の健全性 基準チェック /36
Strides Pharma Scienceの総株主資本は₹22.1B 、総負債は₹22.2Bで、負債比率は100%となります。総資産と総負債はそれぞれ₹59.9Bと₹37.7Bです。 Strides Pharma Scienceの EBIT は₹6.7Bで、利息カバレッジ比率2.7です。現金および短期投資は₹2.5Bです。
主要情報
100.0%
負債資本比率
₹22.15b
負債
| インタレスト・カバレッジ・レシオ | 2.7x |
| 現金 | ₹2.47b |
| エクイティ | ₹22.15b |
| 負債合計 | ₹37.75b |
| 総資産 | ₹59.90b |
財務の健全性に関する最新情報
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Recent updates
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?
Jan 26The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It
Jan 11
財務状況分析
短期負債: STARの 短期資産 ( ₹30.9B ) が 短期負債 ( ₹29.6B ) を超えています。
長期負債: STARの短期資産 ( ₹30.9B ) が 長期負債 ( ₹8.1B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: STARの 純負債対資本比率 ( 88.9% ) は 高い と見なされます。
負債の削減: STARの負債対資本比率は、過去 5 年間で67.5%から100%に増加しました。
債務返済能力: STARの負債は 営業キャッシュフロー によって 十分にカバー されています ( 36.9% )。
インタレストカバレッジ: STARの負債に対する 利息支払い は EBIT ( 2.7 x coverage) によって 十分にカバーされていません。